-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US00370M1036 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 123.7778 |
|---|---|
| Beta | -0.11 |
| Market Cap | 8B |
| PE Ratio | None |
| Dividend Yield | None |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ABVX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026